Insulin glargine

From WikiMD's Food, Medicine & Wellness Encyclopedia

(Redirected from Toujeo)

Insulin Glargine[edit | edit source]

Molecular structure of Insulin Glargine

Insulin Glargine, commonly known under the brand name Lantus, is a long-acting insulin analog used to control blood sugar levels in patients with diabetes. This laboratory-made hormone is designed to provide more consistent blood sugar control compared to regular insulin.

Overview[edit | edit source]

Insulin Glargine is a recombinant form of insulin, used primarily for the management of Type 1 and Type 2 diabetes. It helps in regulating the metabolism of carbohydrates, fats, and proteins by promoting the absorption of glucose from the blood into liver, fat, and skeletal muscle cells.

Chemical Structure and Function[edit | edit source]

Insulin Glargine differs from human insulin in its amino acid sequence, which results in a lower solubility at physiological pH. This feature allows for a slower and more predictable absorption rate, ensuring a consistent insulin level for a longer period.

Clinical Use[edit | edit source]

Indications[edit | edit source]

  • Management of Type 1 diabetes
  • Management of Type 2 diabetes, particularly in cases where blood sugar is not adequately controlled by oral antidiabetic drugs

Administration[edit | edit source]

  • Administered via subcutaneous injection
  • Typically used once daily, often at bedtime

Comparisons with Other Insulins[edit | edit source]

Compared to short-acting insulin, Insulin Glargine provides a more stable, peakless, and prolonged insulin release, reducing the risk of nocturnal hypoglycemia.

Side Effects and Precautions[edit | edit source]

While generally well-tolerated, Insulin Glargine may cause side effects such as:

  • Hypoglycemia (low blood sugar)
  • Injection site reactions
  • Allergic reactions in rare cases

Patients should monitor blood sugar levels regularly and adjust the dose under medical supervision.

Pharmacological Classification[edit | edit source]

Insulin Glargine is classified as a long-acting insulin analog and falls under the category of therapeutic insulin.

Development and Approval[edit | edit source]

Developed by Sanofi-Aventis, Insulin Glargine was first approved for medical use in the United States in 2000. Since then, it has become a widely used insulin analog worldwide.

References[edit | edit source]


Insulin glargine Resources
Doctor showing form.jpg
Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Kondreddy Naveen